Treatment-resistant depression means two or more adequate antidepressant trials have failed. The next steps, in rough order, are a fresh diagnostic review, augmentation with lithium or an atypical antipsychotic, Deep TMS, Spravato, and for severe cases ECT. Each has response rates of 30 to 60 percent in this population, and failing one does not predict failing the next.
If you have taken two antidepressants at a proper dose for a proper length of time and you are still depressed, you have what the field calls treatment-resistant depression. The term sounds final. It is not. It is a signal that the standard first steps are exhausted and that a different, and often more effective, set of options applies.
What the term means
The most widely used definition is failure to respond to at least two antidepressants from different classes, each taken at an adequate dose for at least four to six weeks, in the current episode. "Failure" means less than a 50 percent reduction in symptoms. Some definitions also require a trial of psychotherapy.
By that definition, treatment-resistant depression is common. The STAR*D trial, the largest study of sequential depression treatment ever run, found that about a third of patients reached remission on the first antidepressant, roughly another quarter of the remainder on the second step, and that remission rates fell to the low teens by the third and fourth medication steps. Put differently: after two adequate trials, continuing to switch antidepressants has diminishing returns, and that is exactly when the other tools in this article start to earn their place.
Step one is not a new treatment
Before adding anything, a good psychiatrist re-examines the case, because a meaningful share of "treatment-resistant" depression is something else.
- Bipolar spectrum illness. Depression with a history of even brief hypomanic periods responds poorly to antidepressants alone and well to mood stabilizers. This is the most common missed diagnosis in TRD.
- Medical contributors. Hypothyroidism, sleep apnea, anemia, vitamin D or B12 deficiency, chronic pain, and medications such as beta blockers or corticosteroids.
- Substance use. Alcohol, cannabis and others blunt antidepressant response and are often under-reported.
- Adherence and dosing. Trials that were stopped early, taken inconsistently or never titrated to a full dose do not count as failures.
- Psychosocial drivers. An abusive relationship, unresolved grief or chronic occupational stress that no medication will fix.
- Psychotic features. Subtle delusional guilt or nihilism that changes the treatment entirely.
At Stedfast Psychiatry, a treatment-resistant depression consultation starts here: a structured review of every past trial with doses and durations, screening for bipolar disorder, a medical history and labs where indicated, and a conversation about what else is going on in your life.
The options, roughly in order
| Option | What it is | Response in TRD | Time to effect | Main drawbacks |
|---|---|---|---|---|
| Optimize current medication | Full dose, full duration, confirm adherence | Varies | 2 to 6 weeks | Often already done |
| Augmentation | Add lithium, an atypical antipsychotic, thyroid hormone or a second antidepressant | About 25 to 45 percent | 2 to 6 weeks | Side effects of the added drug; lithium monitoring |
| Deep TMS | FDA-cleared magnetic stimulation, 36 sessions over 6 to 9 weeks | About 50 to 65 percent response, one third remission | 3 to 6 weeks | Daily visits; scalp discomfort |
| Spravato (esketamine) | FDA-approved nasal spray, monitored sessions, with oral antidepressant | About 50 to 70 percent response, one third to half remission | Days to 4 weeks | Dissociation; driver needed; ongoing maintenance |
| ECT | Controlled seizure under anesthesia | About 50 to 70 percent remission; higher with psychosis | 1 to 3 weeks | Anesthesia; memory effects; hospital setting |
| MAOI antidepressants | Older class, underused, effective in atypical and resistant depression | Comparable to augmentation in some studies | 4 to 6 weeks | Dietary and drug restrictions |
| Psychotherapy (CBT, behavioral activation) | Structured therapy alongside medical treatment | Adds meaningfully to any of the above | Weeks to months | Time commitment |
Medication augmentation
Adding a second drug to a partially effective antidepressant is the traditional next step and remains reasonable. Lithium has the longest evidence base for augmentation and also reduces suicide risk, but it requires blood level monitoring and kidney and thyroid checks. Atypical antipsychotics such as aripiprazole, brexpiprazole, quetiapine and cariprazine are FDA-approved as adjuncts for major depression, work within a few weeks, and carry metabolic and movement side effects that need monitoring. Thyroid hormone (T3) augmentation showed modest benefit in STAR*D. Bupropion or mirtazapine added to an SSRI is common and well tolerated. The augmentation step is often worth one try. Repeated cycles of augmentation after that have diminishing returns.
Deep TMS
TMS is where I steer most patients after two failed medications and one augmentation attempt, and sometimes sooner. It has no systemic side effects, no interactions with other medications, and in sham-controlled trials and large registries produces response in half to two thirds of treatment-resistant patients, with about a third reaching remission. The cost is time: 36 sessions over six to nine weeks at our Palm Beach Gardens office. Insurance and Medicare cover it once two medication failures are documented.
Spravato
Spravato is FDA-approved specifically for treatment-resistant depression and is the fastest-acting option short of ECT. Response rates in trials were similar to TMS, with effects sometimes beginning within days. It involves twice-weekly monitored sessions for four weeks, then ongoing maintenance, and the dissociation and driving restriction are real considerations. We offer it at three Palm Beach County offices. Choosing between TMS and Spravato depends on urgency, schedule, preference and insurance; some patients do both in sequence.
ECT
ECT remains the most effective treatment for severe depression, with remission rates well above any other option, and it is the right first choice when depression is psychotic, catatonic, or dangerous enough that a six-week wait is unacceptable. The trade-offs are anesthesia and memory side effects. We refer to hospital-based ECT programs when it is the right call.
Psychotherapy
Treatment-resistant depression is rarely only biological. Cognitive behavioral therapy, behavioral activation and, for chronic depression, the cognitive behavioral analysis system of psychotherapy add to medical treatment and help maintain gains. Therapy alone is rarely sufficient at this stage; therapy alongside any of the options above consistently improves outcomes in trials.
What a realistic plan looks like
For a typical patient arriving after two failed SSRIs, a sequence might be: re-evaluation and labs; one augmentation trial with an atypical antipsychotic or lithium while TMS authorization is obtained; Deep TMS; Spravato if TMS produces a partial response or none; ECT if severity demands it at any point; and psychotherapy throughout. Each step has a defined duration and a measured endpoint, so no one spends months on a treatment that is not working.
Bottom line
Treatment-resistant depression is a stage, not a sentence. After two failed antidepressants, the most effective options are no longer pills, and the response rates for Deep TMS, Spravato and ECT in this population are substantially better than a third or fourth medication switch. The first move is a careful re-evaluation; the second is choosing among those options with a psychiatrist who offers more than one.
Frequently asked questions
How is treatment-resistant depression diagnosed?
By history. If you have taken two antidepressants from different classes, each at an adequate dose for at least four to six weeks, without a 50 percent improvement in symptoms, you meet the common definition. A psychiatrist confirms the trials were adequate and screens for other explanations such as bipolar disorder or medical conditions.
What is the most effective treatment for treatment-resistant depression?
ECT has the highest remission rates, around 50 to 70 percent, but requires anesthesia and causes memory side effects. Deep TMS and Spravato each produce response in roughly half to two thirds of patients with far milder side effects, which is why they are usually tried first unless the situation is urgent.
Should I try TMS or Spravato first?
Both are reasonable. Spravato acts faster and suits urgent situations or people who cannot attend daily visits; TMS has no dissociation, no driving restriction and no ongoing maintenance for most responders. Insurance criteria, schedule and personal preference usually decide. Failing one does not predict failing the other.
Does Stedfast Psychiatry treat treatment-resistant depression?
Yes. We offer medication management at all 13 offices and by telehealth, Deep TMS at Palm Beach Gardens, and Spravato at Boynton Beach, Palm Beach Gardens and Royal Palm Beach. We coordinate ECT referrals with hospital programs when needed. Most insurance and Medicare are accepted.
Related reading
- Does TMS Work? What the Evidence Shows
- Spravato vs Ketamine Infusions: An Honest Comparison
- What to Do When Your Antidepressant Stops Working
- Bipolar Depression vs Unipolar Depression: Why the Difference Changes Treatment
This article is educational and does not replace evaluation by a licensed clinician. If you are in crisis, call or text 988.